# CJC-1295 Ipamorelin FAQ: Common Questions, Answered From the Research

> CJC-1295 Ipamorelin FAQ: what it does, whether it works, side effects, comparisons to sermorelin and tesamorelin, FDA status — answered plainly and cited.

The questions people actually ask, answered from the literature — direct first, context and citation after.

## What is CJC-1295 / Ipamorelin good for?

In research terms, the pair is used to raise the body's own growth hormone and the IGF-1 it produces. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. Felt benefits like sleep and recovery are anecdotal.

## Does CJC-1295 raise testosterone?

No study shows CJC-1295 directly raising testosterone; it acts on the GH/IGF-1 axis, not the gonadal axis. What is documented is its GH and IGF-1 effect: a single subcutaneous dose raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults [1]. Any testosterone claim is outside the published data.

## Does CJC-1295 / Ipamorelin work?

For raising GH and IGF-1, the single components clearly work: one subcutaneous CJC-1295 (DAC) dose raised GH two- to ten-fold for six or more days and IGF-1 for nine to eleven days [1], and ipamorelin releases GH potently and selectively [2]. Whether the *fixed blend* delivers felt benefits is untested — it has never been in a controlled trial.

## What does CJC-1295 and Ipamorelin do?

They press two different switches that both trigger GH release. CJC-1295 mimics GHRH and ipamorelin activates the ghrelin receptor; together they raise GH supra-additively, since the two act through independent mechanisms [3], which the liver converts to IGF-1. A single CJC-1295 (DAC) dose sustained elevated GH for six or more days and IGF-1 for nine to eleven days [1].

## Does CJC-1295 / Ipamorelin increase testosterone?

The published literature does not show a testosterone increase; the pair targets the GH/IGF-1 axis. The measured effect is endocrine in a different lane: a single subcutaneous CJC-1295 (DAC) dose raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults [1]. Testosterone is not a documented outcome.

## What are the bad side effects of CJC-1295 and Ipamorelin?

Class data points to raised blood glucose from reduced insulin sensitivity as the chief metabolic concern, with long-term cancer and mortality data still needed [6]. Notably, ipamorelin is selective: even at doses over 200 times its half-maximal GH dose it did not raise ACTH or cortisol above GHRH-stimulated levels [2]. Users also report fluid retention, tingling, and injection-site reactions — anecdotal.

## How long do CJC-1295 and Ipamorelin take to work?

Endocrine effects are fast and long for the DAC form: a single subcutaneous CJC-1295 (DAC) dose raised GH within the dosing window and held IGF-1 elevated for nine to eleven days, with GH up for six or more days [1]. Ipamorelin's GH pulse peaks around 40 minutes in rodent models. Felt effects like sleep, when reported, are anecdotally described within the first week or two.

## How many mg of CJC-1295 and Ipamorelin should I take?

This site gives no human dose. Neither peptide is FDA-approved and the fixed blend has never been trialed, so there is no established human dose to cite. Research figures exist only as study context — for example CJC-1295 (DAC) was given at 30 to 90 µg/kg subcutaneously in Phase 1 pharmacokinetic work [1] — which is not a protocol and not transferable to personal use.

## Does Ipamorelin reduce belly fat?

No trial of ipamorelin shows belly-fat reduction, and one mouse study even found a GH-independent fat-gain effect via appetite. The closest evidence is from the GHRH analogue tesamorelin: a 2026 meta-analysis of five RCTs found reduced visceral fat (-27.71 cm²) and hepatic fat (-4.28%) [7] — a different compound, offered as read-across, not a result for ipamorelin.

## What are the downsides to CJC-1295 / Ipamorelin?

The real downsides: no FDA approval, no trial of the fixed blend, no long-term human safety database, and a class-level glucose/insulin signal [6]. The two halves also run on mismatched timescales — CJC-1295 (DAC) lasts days while ipamorelin clears in hours — so net GH exposure is uncharacterized. Reported nuisances include puffiness, tingling, and flushing, all anecdotal.

## Which is better, Sermorelin or Ipamorelin?

Neither is "better" — they do different jobs and are often paired. Sermorelin is a short-acting GHRH analogue (the same family as CJC-1295); ipamorelin is a ghrelin-receptor secretagogue. Because the two families act through independent pathways, combining a GHRH arm with a secretagogue arm releases GH synergistically [3]. They are complementary, not competing.

## Can you take both Sermorelin and Ipamorelin together?

Combining a GHRH analogue with a GH-releasing peptide is exactly the synergy strategy the literature describes: in normal men, submaximal GHRP doses combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms [3]. That is the rationale for pairing a GHRH-type agent with ipamorelin. This is mechanism, not a dosing endorsement.

## Is Tesamorelin better than Ipamorelin?

They are different tools. Tesamorelin is a GHRH analogue with the strongest human body-composition data of the group — a 2026 meta-analysis of five RCTs found reduced visceral fat (-27.71 cm²) and hepatic fat (-4.28%) with increased lean mass [7]. Ipamorelin is the ghrelin-receptor partner with rodent-dominant data. "Better" depends on the goal; they are not interchangeable.

## Is Ipamorelin stronger than Sermorelin?

They act on different receptors, so "stronger" is the wrong axis. Ipamorelin is a potent, selective GH secretagogue — matching GHRP-6's GH efficacy without raising cortisol or ACTH even at very high doses [2] — while sermorelin is a GHRH analogue. They are complementary halves, which is why a stack uses one of each rather than picking a winner.

## Which is safer, Sermorelin or Ipamorelin?

Both share the GH-secretagogue class profile, where the main concern is raised blood glucose from reduced insulin sensitivity [6]. Ipamorelin's distinguishing safety feature is selectivity — no rise in ACTH or cortisol above GHRH-stimulated levels even at doses over 200 times its half-maximal GH dose [2]. Neither is FDA-approved, and long-term human safety data for either is limited.

## What is CJC-1295 / Ipamorelin?

It is a research combination of two peptides: CJC-1295, a long-acting GHRH analogue that mimics the body's GH-release signal, and ipamorelin, a selective ghrelin-receptor secretagogue that triggers a clean GH pulse [2]. Used together they raise GH and IGF-1. Neither is FDA-approved, and the fixed combination has never been tested in a controlled trial.

## How much CJC-1295 / Ipamorelin should I take?

No human dose is provided here. There is no approved or validated human dose for either peptide or for the blend, which has never been trialed. Studies used research doses for measurement only — CJC-1295 (DAC) at 30 to 90 µg/kg subcutaneously in Phase 1 work [1], ipamorelin mostly in animal models — none of which is a personal-use recommendation.

## Is CJC-1295 / Ipamorelin safe?

There is no safety database for the fixed blend, which was never trialed. The broader GH-secretagogue class is generally well tolerated short-term, with raised blood glucose the chief concern and long-term cancer/mortality data still needed [6]. Ipamorelin is notably selective, sparing ACTH and cortisol even at very high doses [2]. Unverified research-grade purity adds further uncertainty.

## Is Ipamorelin FDA approved?

No. Ipamorelin is not FDA-approved for any human indication, nor is CJC-1295; both are sold only as research chemicals. A GH-secretagogue review frames the class as well tolerated overall but emphasizes that long-term and large-population safety data are lacking [6]. Both peptides are also prohibited at all times in sport under WADA Section S2.

## How to reconstitute CJC-1295 / Ipamorelin (5mg)?

This site does not give reconstitution instructions, as that crosses into use guidance. In a laboratory-handling sense, lyophilised peptide is dissolved in bacteriostatic water (sterile water with 0.9% benzyl alcohol), kept refrigerated, and used within weeks before deamidation degrades it. Specific volumes and doses are deliberately not provided here — this is a research digest, not a protocol.

## Where to inject CJC-1295 / Ipamorelin?

Injection-site guidance is outside what this editorial digest provides. In the studies, the route was subcutaneous (and sometimes intravenous), and community reports of injection-site redness or itching note that site rotation is the usual suggestion — but that is anecdote, not instruction. No how-to is given here.

## Does Ipamorelin make you hungry / increase appetite?

Plausibly, yes — ipamorelin acts on the ghrelin receptor, the body's hunger switch, and increased appetite is frequently reported by users shortly after dosing. A GH-secretagogue review notes the class is generally well tolerated, with the glucose effect as the chief metabolic concern [6]; the appetite effect is consistent with the ghrelin-receptor mechanism but is reported anecdotally, not measured for this blend.

---

A graphene-lab readout of the CJC-1295 and ipamorelin literature — the GH and IGF-1 numbers, the DAC-versus-Mod-GRF half-life split, and the selectivity data logged to source, with the empty space where the fixed-blend trial should be left lit on the panel; no clinic behind the console and nothing here dosed, dispensed, or sold.